While loss of BRCA1 promoter methylation during therapy has been described in ovarian cancer [41], notably, such loss of methylation may not explain therapy resistance in the TNT trial since methylation status was determined in samples collected at trial inclusion [7]. Here, BRCA1 is linked to ovarian carcinoma.